CSBR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CSBR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Champions Oncology's operating assets for the quarter that ended in Jan. 2024 was $22.32 Mil. Champions Oncology's operating liabilities for the quarter that ended in Jan. 2024 was $21.10 Mil. Champions Oncology's Total Assets for the quarter that ended in Oct. 2023 was $28.29 Mil. Therefore, Champions Oncology's scaled net operating assets (SNOA) for the quarter that ended in Jan. 2024 was 0.04.
The historical data trend for Champions Oncology's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology Annual Data | |||||||||||||||||||||
Trend | Apr14 | Apr15 | Apr16 | Apr17 | Apr18 | Apr19 | Apr20 | Apr21 | Apr22 | Apr23 | |||||||||||
Scaled Net Operating Assets | Get a 7-Day Free Trial | -0.12 | 0.05 | 0.60 | 0.35 | 0.09 |
Champions Oncology Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Scaled Net Operating Assets | Get a 7-Day Free Trial | 0.12 | 0.09 | 0.16 | 0.09 | 0.04 |
For the Biotechnology subindustry, Champions Oncology's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Champions Oncology's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Scaled Net Operating Assets falls into.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Champions Oncology's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Apr. 2023 is calculated as
Scaled Net Operating Assets (SNOA) | (A: Apr. 2023 ) | ||||
= | (Operating Assets (A: Apr. 2023 ) | - | Operating Liabilities (A: Apr. 2023 )) | / | Total Assets (A: Apr. 2022 ) |
= | (24.193 | - | 21.076) | / | 35.378 |
= | 0.09 |
where
Operating Assets | (A: Apr. 2023 ) | ||
= | Total Assets | - | Cash, Cash Equivalents, Marketable Securities |
= | 34.311 | - | 10.118 |
= | 24.193 |
Operating Liabilities | (A: Apr. 2023 ) | ||||
= | Total Liabilities | - | Long-Term Debt & Capital Lease Obligation | - | Short-Term Debt & Capital Lease Obligation |
= | 29.675 | - | 7.391 | - | 1.208 |
= | 21.076 |
Champions Oncology's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jan. 2024 is calculated as
Scaled Net Operating Assets (SNOA) | (Q: Jan. 2024 ) | ||||
= | (Operating Assets (Q: Jan. 2024 ) | - | Operating Liabilities (Q: Jan. 2024 )) | / | Total Assets (Q: Oct. 2023 ) |
= | (22.319 | - | 21.103) | / | 28.294 |
= | 0.04 |
where
Operating Assets | (Q: Jan. 2024 ) | ||
= | Total Assets | - | Cash, Cash Equivalents, Marketable Securities |
= | 26.787 | - | 4.468 |
= | 22.319 |
Operating Liabilities | (Q: Jan. 2024 ) | ||||
= | Total Liabilities | - | Long-Term Debt & Capital Lease Obligation | - | Short-Term Debt & Capital Lease Obligation |
= | 28.845 | - | 6.437 | - | 1.305 |
= | 21.103 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Champions Oncology's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Newman Mendelson | director | COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817 |
Ronnie Morris | director, officer: President | 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205 |
Philip P. Breitfeld | director | ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601 |
New Enterprise Associates 14, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Neeraj Agrawal | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Roger H Lee | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Michael Maurice Brown | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Battery Management Corp. | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
R David Tabors | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Jesse Feldman | 10 percent owner | ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
Joel Ackerman | director, officer: Chief Executive Officer | COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817 |
Patrick J Kerins | 10 percent owner | |
Ryan D Drant | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Nea 14 Gp, Ltd | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Nea Partners 14, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
From GuruFocus
By GF Value GF Value • 04-11-2021
By ACCESSWIRE • 09-14-2023
By ACCESSWIRE ACCESSWIRE • 09-03-2021
By ACCESSWIRE • 08-22-2023
By ACCESSWIRE • 08-01-2023
By ACCESSWIRE ACCESSWIRE • 07-14-2021
By ACCESSWIRE ACCESSWIRE • 10-20-2021
By ACCESSWIRE ACCESSWIRE • 02-15-2022
By ACCESSWIRE • 07-21-2023
By ACCESSWIRE • 09-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.